z-logo
open-access-imgOpen Access
Análisis in silico de lipocalinas de perro, gato, caballo, vaca, hámster y gallina. Posible efecto en el estudio de las enfermedades alérgicas
Author(s) -
Andrés Sánchez,
Ricardo Cardona
Publication year - 2016
Language(s) - English
Resource type - Journals
ISSN - 2448-9190
DOI - 10.29262/ram.v63i1.95
Subject(s) - lipocalin , population , biology , sensitization , medicine , immunology , environmental health
Background: Lipocalins seem to explain the cross-reactivity between some pets like cat and dog. However, little has been studied its role in other animals and its possible clinical impact in allergy diseases.Objective: Analyzed by bioinformatics techniques, the identity between lipocalin of some animals and explore the clinical impact in allergic diseases.Methods: The search for lipocalin sequences was performed using the BLAST program of NCBI Database. The protein sequences were aligned with CLUSTAL Omega UniProt version 1.2.1 software. The base sequence for alignments were lipocalins dogs and cats. The defined percentage identity was compared with the frequency of sensitization to animals exposed in a population of 288 patients with suspected allergic diseases.Results: Identities between sequences were 10% to 70%. The highest values were found with Can f 6 - Fel d 4 (68%) and Fel d 4 - Equ c 1 (68%). The lower identitiy was found with lipocalin porpurin and retinol binding (<20%). We observed a relationship between sensitization and the percent identity between the species studied.Conclusions: In conclusion, lipocalins as Can f 6, Fel de 4 and Equ c 1 seem to play an important role in the cross-reactivity to cat, horse and dog but not for the co-sensitization to hamster, cow or birds.  Fel de 4 and Equ c 1 could be a prevalent allergen for horse and cat. These results come from predictive analysis and must be confirmed by in vitro and in vivo studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here